Outcomes of Once-Daily ICS/LABA/LAMA + PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations

NCT05292053 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Copd

Interventions

DRUG: TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation

Sponsor

Baylor Research Institute

Collaborators

[object Object]